Livin, a Novel Inhibitor of Apoptosis Protein Family Member*

Gary M. Kasof and Bruce C. GomesDagger

From AstraZeneca Pharmaceuticals, Enabling Sciences and Technology, Wilmington, Delaware 19803

Received for publication, May 1, 2000, and in revised form, October 6, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

A novel human inhibitor of apoptosis protein (IAP) family member termed Livin was identified, containing a single baculoviral IAP repeat (BIR) domain and a COOH-terminal RING finger domain. The mRNA for livin was not detectable by Northern blot in most normal adult tissues with the exception of the placenta, but was present in developmental tissues and in several cancer cell lines. Highest levels were observed in two melanoma-derived cell lines, G361 and SK-Mel29. Transfection of livin in HeLa cells resulted in protection from apoptosis induced by expression of FADD, Bax, RIP, RIP3, and DR6. Similar to other IAP family members, the anti-apoptotic activity of Livin was dependent on the BIR domain. Livin was also capable of inhibiting DEVD-like caspase activity triggered by tumor necrosis factor-alpha . In vitro binding studies demonstrated a direct interaction between Livin and the active form of the downstream caspases, caspase-3 and -7, that was dependent on the BIR domain of Livin. In addition, the unprocessed and cleaved forms of caspase-9 co-immunoprecipitated with Livin in vivo, and recombinant Livin could inhibit the activation of caspase-9 induced by Apaf-1, cytochrome c, and dATP. The subcellular distribution of the transfected Livin was analyzed by immunofluorescence. Both Livin and Survivin were expressed in the nucleus and in a filamentous pattern throughout the cytoplasm. In contrast to the apoptotic activity, the COOH-terminal RING domain mediated its subcellular localization patterning. Further studies found that transfection of an antisense construct against livin could trigger apoptosis specifically in cell lines expressing livin mRNA. This was associated with an increase in DNA fragmentation and in DEVD-like caspase activity. Thus, disruption of Livin may provide a strategy to induce apoptosis in certain cancer cells.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The inhibitor of apoptosis protein (IAPs)1 family is characterized by one or more repeats of a highly conserved ~70 amino acid domain termed the baculoviral IAP repeat (BIR) and suppress apoptosis triggered by a wide variety of stimuli, including viral infection, chemotherapeutic drugs, staurosporin, growth factor withdrawal, and by components of the tumor necrosis factor-alpha (TNF-alpha )/Fas apoptotic signaling pathways (1-3). While first identified in baculovirus, the IAP family has been conserved evolutionarily from viruses to nematodes, flies, and several mammalian species. There are currently five human IAP family members, c-IAP1, c-IAP2, XIAP, NAIP, and Survivin (4-7). All of the human IAP family members, with the exception of NAIP, have been shown to interact with specific cysteine proteases, or caspases, required for the cleavage of certain proteins involved in the disassembly of the cell during apoptosis (8). The caspases are synthesized as inactive zymogen forms which upon apoptotic stimulation are proteolytically processed in a sequential manner into their active heterotetrameric forms. c-IAP1, c-IAP2, XIAP, and Survivin have been reported to bind to and inhibit the active forms of the terminal caspases-3 and -7, but do not interact with caspases-8, which is the most proximal caspase from the TNF-alpha /Fas receptor (9-12). However, in the case of Survivin, caspase inhibition may be more indirect through association with Cdk4 leading to inhibition of pro-caspase-3 by p21 (13). c-IAP1, c-IAP2, and XIAP also bind to the zymogen form of caspase-9 thereby preventing its proteolytic processing as well as the processing of downstream proteases, such as caspase-3, -6, and -7 (14). Abrogation of caspase activity, a common downstream component of apoptosis, enables IAPs to have widespread anti-apoptotic potential.

The BIR domain forms a novel zinc-fold that is the critical motif for their anti-apoptotic activity and interaction with caspases (15). While many IAPs contain up to three tandem BIR repeats, a single BIR domain is sufficient for caspase interaction and protection from apoptosis (16). Many of the IAP proteins (c-IAP1, c-IAP2, XIAP, as well as viral and insect IAPs) also contain a RING domain near their COOH termini. The role for the RING domain varies depending on the IAP and/or the apoptotic stimulus, but does not appear to be required for the anti-apoptotic activity of human IAPs (10, 16-18). Deletion of the RING domain in c-IAP2 has suggested a critical role in TNF-alpha -mediated NF-kappa B activation, thereby providing an additional mechanism for the IAPs anti-apoptotic activity (19). Recent studies have also found that c-IAP1 and XIAP have ubiquitin ligase activity which leads to their degradation during apoptosis and that this activity is dependent on their RING domain (20). However, it is unclear if this is a general feature of the RING domain in other IAP family members.

Several of the IAP family members have been reported to play a role in pathological conditions, particularly neurodegenerative disorders and cancer. For instance, the NAIP gene was originally identified based on its deletion in patients with spinal muscular atrophy, a neurodegenerative disorder characterized by motor neuron depletion through apoptosis (21). The correlation between NAIP, spinal muscular atrophy, and apoptosis suggests that NAIP may be required for the survival of these neurons and that mutations in the NAIP locus contribute to spinal muscular atrophy. In addition, NAIP levels are transiently elevated following ischemia and damage can be inhibited by overexpression of NAIP in vivo (22). Expression of other IAP family members have been correlated with cancer. For example, XIAP and c-IAP1 are found in most cancer cell lines (23). Survivin is overexpressed in nearly all human tumors and transformed cell lines, but is rarely present in normal adult tissues (4, 11, 24-27). Survivin is induced by angiogenic factors such as vascular endothelial growth factor, fibroblast growth factor, and angiopoietin-1 which may explain its elevated levels in tumors (28, 29). Depletion of Survivin using antisense or dominant negative mutants induces apoptosis implying that Survivin expression contributes to the survival of cancer cells (24, 30-33). Tumors expressing Survivin, as well as other anti-apoptotic signal generally have a poorer prognosis, likely due to their resistance to classical chemotherapy (25).

Here, we attempted to identify novel members of the IAP family via homology searches. One gene was identified which we termed livin that encodes a protein with a single BIR domain and a COOH-terminal RING domain. Expression of Livin inhibited apoptosis by a number of stimuli, whereas an antisense construct was shown to induce apoptosis. Like its other family members, Livin was capable of binding to caspases and could inhibit the proteolytic processing of caspase-9 in vitro. Restricted expression of livin mRNA during development and transformed cell lines suggests a very specific role for Livin.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Plasmid Construction-- A partial cDNA sequence of livin was identified in the proprietary Incyte LifeSeq data base (accession number 1419118). To obtain the full-length construct we screened an adult kidney cDNA library (Life Technologies, Grand Island, NY) with a livin-specific probe, 5'-CCTTCTATGACTGGCCGCTGA-3', using the GeneTrapperTM cDNA positive selection system (Life Technologies, Grand Island, NY). The coding sequence of livin was PCR cloned into pcDNA3.1/V5/His-TOPO (Invitrogen, Carlsbad, CA) in both the sense and antisense orientations. Livin was subsequently subcloned by PCR into the BamHI/EcoRI sites in pGEX-6P (Amersham Pharmacia Biotech, Piscataway, NJ) for purification of a glutathione S-transferase fusion protein. Deletion mutants of Livin (Delta N154, Delta C86, and 86-154) were generated by PCR and subcloned into the KpnI/ApaI sites within pcDNA3.1/myc-His (Invitrogen, Carlsbad, CA). FADD, Bax, and DR6, were subcloned by PCR from Incyte clones 3334311, 2057308, and 2733717 and ligated into pTracer-SV40 (Invitrogen, Carlsbad, CA) at EcoRI/NotI, EcoRV/NotI, and NotI/SpeI sites, respectively. Caspase-9 was prepared by PCR from Incyte clone 3590462 and subcloned into pcDNA3.1/V5/His-TOPO. Apaf-1 was cloned into pcDNA3.1/V5/His-TOPO from a PCR product generated from a human testis cDNA library (CLONTECH, Palo Alto, CA). The pTracer-SV40-RIP plasmid was prepared by PCR from pMH-RIP (34) and ligated into the KpnI/NotI sites in pTracer-SV40. The constructions of pTracer-SV40-RIP3 and pZeoSV2-Bcl-xL were described previously (34). pcDNA3.1-myc-survivin was provided by Dr. Kevin Hudson (AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, UK). The nucleotide sequences of all of the clones were confirmed by fluorescent terminator cycle sequencing using an automated 377 DNA sequencer (PerkinElmer Life Sciences and Applied Biosystems, Foster City, CA).

Production of Recombinant Livin-- pGEX-6P-livin was inoculated overnight in Escherichia coli BL21 and subsequently stimulated with 0.5 mM isopropyl-1-thio-beta -D-galactopyranoside for 4 h. The bacterial pellet was resuspended in phosphate-buffered saline plus lysozyme (1 mg/ml) and lysed by sonication. Lysates were incubated with 1% Triton X-100 for 30 min at 4 °C and then centrifuged to remove the insoluble material. Supernatants were added to a glutathione-Sepharose 4B column and the bound protein was eluted with PreScission protease (Amersham Pharmacia Biotech, Piscataway, NJ) thereby cleaving the glutathione S-transferase fusion.

Maintenance of Cell Lines-- HeLa, G361, SK-Mel29, HMCB, A375, WM115, HT144, and SW480 cell lines (ATCC, Rockville, MD) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and penicillin (100 units/ml)/streptomycin (0.1 mg/ml). The cells were maintained at 37 °C, 5% CO2. Transfections were performed using LipofectAMINE Plus (Life Technologies, Grand Island, NY) according to the manufacturer's specifications.

Purification of RNA and Northern Blotting-- Poly(A) RNA was isolated from human melanoma cell lines (SK-Mel29, HMCB, A375, WM115, and HT144) using the Poly(A) Pure kit (Ambion, Austin, TX) according to the manufacturer's specifications. The RNA was denatured in sample buffer (2.2 M formaldehyde, 50% formamide, 50 mM MOPS (pH 7.0), and 1 mM EDTA) heated at 65 °C for 10 min, electrophoresed in a 1% agarose gel containing 2.2 M formaldehyde, 50 mM MOPS (pH 7.0), and 1 mM EDTA, and then transferred by capillary elution onto Hybond-N nylon filters (Amersham Pharmacia Biotech). In addition, we used commercially available human RNA blots, prepared from adult and fetal tissues and cancer cell lines (CLONTECH, Palo Alto, CA). The blots were hybridized to random primed radiolabeled livin (full-length cDNA containing 5'- and 3'-untranslated region) or actin (CLONTECH, Palo Alto, CA) incubated in Hybrisol I (Oncor, Gaithersburg, MD) overnight at 42 °C. The blots were then washed with 2 × SSC + 0.05% SDS at room temperature followed by high stringency washing, 0.1 × SSC + 0.1% SDS at 50 °C, and visualized using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).

GFP Viability Assays-- Viability was assessed using the green fluorescent protein (GFP) marker produced from pTracer-SV40-derived vectors. Transfected cells were fixed with 2% paraformaldehyde in phosphate-buffered saline, counterstained with 10 µg/ml propidium iodide, 200 µg/ml RNase A, and 0.1% Tween 20 for 30 min at room temperature, and then mounted on microscope slides with Immu-mount (Shandon, Pittsburgh, PA). A laser scanning cytometer (CompuCyte, Cambridge, MA) was used to determine the percent of GFP-positive cells. The propidium iodide staining served as a marker required for gating the cell population. Relative fluorescence values were determined with an excitation at 488 nm using an argon laser and emission filters at 505-540 nm (GFP) and 614-639 nm (propidium iodide).

TUNEL Assay-- The ability of antisense against livin to induce apoptosis was examined using TdT-mediated dUTP-X nick end labeling (TUNEL). Transiently transfected cells were stained with fluorescein isothiocyante-conjugated dUTP according to the manufacturer's specifications (Roche Molecular Biochemicals, Indianapolis, IN). The cells were then counterstained with 10 µg/ml propidium iodide and 200 µg/ml RNase A, and collected on microscope slides by a cytospin. The percent of TUNEL-positive cells was evaluated using the laser scanning cytometer as described above for GFP.

Caspase Activity Assays-- Caspase activity was measured using the ApoAlertTM caspase-3 fluorescent assay kit (CLONTECH). Cytosolic lysates were prepared from transiently transfected cells and incubated with 50 µM of the fluorescent substrate 7-amino-4-trifluoromethyl coumarin (AFC) conjugated to the caspase cleavage site Asp-Glu-Val-Asp (DEVD) for 1 h at 37 °C. Hydrolyzed AFC was detected using a CytoFluorTM 4000 fluorometer (PerSeptive Biosystems, Framingham, MA) with peak excitation/band width at 360/40 nm and peak emission/band width at 530/30 nm. In vitro processing of caspase-9 was performed using [35S]methionine-labeled caspase-9 and Apaf-1 prepared using the TNT T7 reticulocyte lysate system (Promega Corp., Madison, WI). The proteins were desalted and exchanged into buffer A (20 mM HEPES (pH 7.5), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, and 1 mM dithiothreitol) using a Bio-spin P-6 column (Bio-Rad, Hercules, CA). Caspase-9 (2 µl) and Apaf-1 (6 µl) were combined with 10 µM cytochrome c and 1 mM dATP (Sigma) and 50 µM recombinant Livin for 1 h at 30 °C. The samples were boiled in Laemmli buffer, and resolved by 4-20% SDS-PAGE. Gels were fixed in 50% methanol, 10% acetic acid for 1 h, dried, and then visualized using a PhosphorImager.

In Vitro Binding Assay-- In vitro binding reactions were performed by combining recombinant active caspase-3 or -7 (PharMingen, San Diego, CA) with [35S]methionine-labeled Survivin or Livin (wild-type and deletion mutants), prepared using the TNT T7 reticulocyte lysate system. Samples were incubated with polyclonal antibodies against either caspase-3 or -7 (PharMingen, San Diego, CA) in 0.5 ml of NETN buffer (20 mM Tris (pH 8.0), 100 mM NaCl, 1 mM EDTA, and 0.2% Nonidet P-40) for 1.5 h at 4 °C followed by protein G-Sepharose (Amersham Pharmacia Biotech) for 30 min. All samples were then washed three times in NETN buffer, resolved by SDS-PAGE, and detected using a PhosphorImager.

Binding kinetics were obtained using the BiacoreTM 3000 (Biacore, Piscataway, NJ). Recombinant Livin was amine coupled to a CM5 sensor chip and 1-500 nM active caspases-3, -7, and -9 were passed through the chip. Binding constants were determined using the BIAevaluation software (version 3.0).

Immunoprecipitations and Western Blotting-- Associations with caspase-9 were shown using HeLa cells transiently transfected with either pcDNA3.1/V5/His-TOPO-livin or pcDNA3.1-myc-survivin and treated with TNF-alpha and cycloheximide. Cell lysates were prepared in 1 ml of RIPA buffer (0.01 M sodium phosphate (pH 7.2), 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 1% Nonidet P-40, 1% sodium deoxycholate, and 0.1% SDS) supplemented with a protease inhibitor mixture tablet (Roche Molecular Biochemicals, Indianapolis, IN) which were spun at 20,000 × g for 30 min at 4 °C. The soluble supernatants were immunoprecipitated using either a monoclonal antibody against V5 (Invitrogen, Carlsbad, CA) followed by protein G-Sepharose or with a monoclonal antibody against Myc conjugated to agarose (Santa Cruz Biotechnology, Santa Cruz, CA). The samples were washed three times in RIPA buffer, boilied in Laemmli buffer, and resolved by SDS-PAGE. The gels were semi-dry blotted onto nitrocelluose and probed with a monoclonal antibody against caspase-9 (PanVera Corp., Madison, WI). Immuno-complexes were detected by enhanced chemiluminescence (ECL) according to the manufacturer's specifications (Amersham Pharmacia Biotech).

Western blots were performed to confirm that the antisense construct of livin could reduce Livin expression, but not Survivin. Transfected HeLa cells were maintained in 100 µM ZVAD-fmk (Enzyme Systems, Livermore, CA) to prevent apoptosis. Cell lysates were prepared in Laemmli buffer and Western blots were performed as described above using antibodies against V5, Survivin (R & D Systems, Minneapolis, MN), and glyceraldehyde-3-phosphate dehydrogenase (Chemicon International, Inc., Temecula, CA).

Immunofluorescence-- The subcellular localizations of Livin and Survivin were assessed by indirect immunofluorescence from HeLa cells transfected with epitope-tagged expression constructs. Twenty-four hours post-transfection the cells were fixed with 2% paraformaldehyde and then permeabilized with 0.2% Triton X-100 in phosphate-buffered saline. Coverslips were incubated with antibodies against the V5 or Myc (Oncogene Research Products, Cambridge, MA) epitopes for 1 h at 37 °C. Staining was detected using a fluorescein isothiocyante-conjugated goat anti-mouse antibody (Life Technologies, Grand Island, NY) for 1 h at 37 °C. Cells were visualized by epifluorescence using an Olympus AX70 microscope equipped with a Kodak DCS 520 digital camera (Hitech Instruments, Inc., Edgemont, PA).


    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Identification and Expression of Livin-- A homology search of a proprietary Incyte data base using BLAST, revealed an 840-nucleotide sequence present in a fetal kidney library and predicted to encode a novel protein with a BIR domain and a COOH-terminal RING finger domain (accession number 1419118). To obtain the full-length gene, we used the GeneTrapperTM cDNA positive selection system to screen an adult kidney cDNA library. A low abundant clone was found which contained an in-frame stop codon in the 5'-untranslated region, suggesting it was a full-length gene. This gene, which we termed livin, was 1297 base pairs and predicted to encode a 280-amino acid protein (Fig. 1A; GenBank accession number AF311388). Genomic sequence corresponding to the livin cDNA was found in the EMBL data base (accession number AL121827) and localized on chromosome 20. The overall protein identity of Livin to other IAP family members based on the GAP pairwise sequence alignment (GCGTM, Madison, WI) was 24.1% to c-IAP1, 26.1% to c-IAP2, 34.7% to XIAP, 25.5% to NAIP, and 26.3% to Survivin. At a structural level it was similar to Survivin with respect to having just a single BIR domain (Fig. 1B). However, Livin did not have a coiled-coil domain like Survivin, but rather contained a COOH-terminal RING domain found in c-IAP1, c-IAP2, and XIAP.



View larger version (65K):
[in this window]
[in a new window]
 
Fig. 1.   Nucleotide and amino acids sequences of livin. A, the BIR domain is indicated in bold, and the RING domain is underlined. B, homology between the BIR domains of Livin and other IAP family members were determined using the Clustal algorithm from the MegAlign software (DNASTAR). In cases where the IAPs had three BIR domains (c-IAP1, c-IAP2, XIAP, and NAIP), the second BIR domain is represented due to evidence from XIAP that the middle BIR has a more critical role in suppressing apoptosis. Shading indicates identical residues among family members.

The tissue distribution of livin was studied by Northern blotting with mRNA prepared from human adult and developmental tissues as well as several cancer cell lines. Using the entire cDNA sequence of livin as a probe, three distinct mRNAs were detected with approximate sizes of 1.4, 2.0, and 2.8 kilobases (Fig. 2). The smaller of the transcripts was consistent with the cDNA isolated in our screen. The sizes of the three transcripts were distinct from other IAP family members, suggesting that they were specific for livin. Despite the presence of livin in fetal and adult kidney cDNA libraries, within the normal tissues tested here, livin was found only in placenta and fetal brain. It is likely that livin is expressed transcriptionally in other tissues, but at levels too low to be detected by the Northern blot. Elevated levels of livin were seen in cancer cell lines, particularly in the melanoma cell lines G361 and SK-Mel29, and to a lesser extent, in HeLa (Fig. 2). Interestingly, the segments of the chromosome corresponding to the livin locus displays increased copy number in nearly all melanoma cell lines and primary tumors (35). While livin has a narrower distribution than survivin in cancer cells, the general patterns of expression between these genes are similar, with no detectable expression in normal adult tissues and elevated levels in placenta, developing tissues, and cancer cell lines (4, 11).



View larger version (38K):
[in this window]
[in a new window]
 
Fig. 2.   Expression of livin. Northern hybridization were performed from multiple tissue blots prepared from adult and fetal mRNA as well as from several cancer cell lines. Each lane contains 2 µg of poly(A)- RNA. Blots were probed against livin and an actin control. PBL, peripheral blood leukocytes.

Anti-apoptotic Activity of Livin-- While the BIR motif can confer an anti-apoptotic signal via caspase interactions, some BIR motifs are not as effective at suppressing apoptosis, and there are BIR-containing proteins with no apparent anti-apoptotic function (16, 18, 36). Therefore, not all BIR domain-containing proteins may be defined properly as an IAP. The potential anti-apoptotic activity of Livin was investigated with respect to several pro-apoptotic signals acting at different points within the apoptotic process, including DR6, FADD, RIP, RIP3, and Bax. DR6 is a member of the TNF receptor family and thus is at the most upstream level of the apoptotic process (37). FADD (38), RIP (39), and RIP3 (40, 41) are adapter proteins within the TNF-alpha /Fas pathway. Bax is a potent inducer of apoptosis but may not have a direct role in TNF-alpha /Fas pathway (42). HeLa cells were transfected with these apoptotic genes in the pTracer vector containing a GFP marker for accessing viability. Transfection with any of the pro-apoptotic genes led to roughly a 90% reduction in viability, as compared with empty pTracer vector (Fig. 3A). Co-transfection of the apoptotic genes with either livin or survivin provided a 4-6-fold increase in viability. In general, the anti-apoptotic activity of Livin appeared to be slightly more robust than Survivin although that may be due to small differences in protein expression. Levels of Livin and Survivin were monitored by Western blotting and were comparable (data not shown). Survivin has been shown previously to be less effective at inhibiting apoptosis than other IAP family members (11). These results clearly demonstrate that Livin is a novel member of the IAP family capable of inhibiting apoptosis by several stimuli.



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 3.   Livin suppresses apoptosis by multiple stimuli. A, HeLa cells (2 × 105) were co-transfected with 1 µg of pTracer-SV40 derived plasmids containing the apoptotic genes (dr6, fadd, rip, rip3, bax) along with 1 µg of pcDNA3.1-myc-survivin, pcDNA3.1/V5/His-TOPO-livin, or empty pcDNA3.1 vector. B, HeLa cells were co-transfected with 1 µg of pTracer-SV40-RIP3, or empty pTracer-SV40 vector, and 1 µg of pcDNA3.1/myc-His-livin-Delta N154, -Delta C86, and -86-154, or empty pcDNA3.1 vector. Twenty-four hours post-transfection GFP levels were measured by laser scanning cytometry. At least 5000 cells were analyzed for each transfection. The graphs indicate relative viability which was calculated based on the percent of GFP-positive cells as compared with the control, empty pTracer-SV-40 with pcDNA3.1. Error bars represent standard error of the mean, n = 3.

To determine the regions of Livin necessary for its anti-apoptotic activity, three deletion mutants comprising the NH2-terminal (Delta C86; amino acids 1-86), the central BIR domain (86-154; amino acids 86-154), or the COOH-terminal RING domain (Delta N154; amino acids 154-280) were tested for their ability to block RIP3-mediated apoptosis. While the BIR domain is the critical region for anti-apoptotic activity within the IAP family, there may be some variations depending on the particular IAP and/or apoptotic stimulus. For example, a single BIR domain from c-IAP1, c-IAP2, or XIAP is sufficient for inhibiting caspase activity and etoposide-mediated apoptosis (10, 16), whereas the BIR domain from Survivin is not sufficient for inhibiting Taxol-induced apoptosis (32). In addition, the baculoviral IAPs require both the BIR domain and the RING domain for their anti-apoptotic activity (18). Site-directed mutagenesis of XIAP revealed that actually the region adjacent to the BIR domain may play an important role in its activity (43). Here, it was found that the BIR domain of Livin was sufficient for inhibiting RIP3-mediated apoptosis, and was nearly as effective as the wild-type protein (Fig. 3B). The NH2- and COOH-terminal fragments could be detected by immunofluorescence but had no effect on apoptosis triggered by RIP3. Thus, the BIR domain of Livin appears to be the critical motif involved in blocking apoptosis.

Livin Inhibits Caspase Activity and Binds to Caspase-3, -7, and -9-- Several IAP family members including XIAP, c-IAP1, and c-IAP2 directly bind to pro-caspase-9 and prevent its processing (14). An association has also been observed between pro-caspase-9 and a cleaved product of XIAP containing its BIR3 and RING domains, and therefore presumably has a similar structure to Livin (44). Possible interactions between Livin and/or Survivin with caspase-9 were tested in HeLa cells transfected with these IAP family members. The cells were subsequently treated with TNF-alpha to evaluate interactions with activated caspase-9, or left untreated to examine the unprocessed form. Cell lysates were immunoprecipitated with antibodies against the epitope tags on Livin (V5) and Survivin (Myc) and then probed by Western blot for caspase-9. In the absence of TNF-alpha , Livin, but not Survivin, immunoprecipitated with the unprocessed 45-kDa form of caspase-9 (Fig. 4A). Upon stimulation with TNF-alpha , an increase in binding was observed between Livin and the 35-kDa cleaved form of caspase-9. Both Survivin and Livin were expressed in the lysates (Fig. 4B). These data demonstrate an association between Livin and pro-caspase-9 and a partially activated form of caspase-9 containing the NH2-terminal prodomain. No interaction of Livin was seen with the fully active 12- and 20-kDa subunits of caspase-9 using the Biacore, suggesting that the prodomain is required for the interaction.



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Livin interacts with caspase-9 and inhibits its processing. A, HeLa cells (1 × 106) either untransfected or transfected with 4 µg of pcDNA3.1/V5/His-TOPO-livin or pcDNA3.1-myc-survivin were treated with or without TNF-alpha (1000 units/ml) and cycloheximide (30 µg/ml) for 2 h. Cell lysates were prepared in RIPA buffer and immunoprecipitated with antibodies against V5 or Myc. The samples were then resolved by SDS-PAGE, transferred onto nitrocellulose, and probed with an antibody against the NH2-terminal of caspase-9. The unprocessed 45-kDa and cleaved 35-kDa forms of caspase-9 recognized by the antibody are indicated. Heavy and light chains of immunoglobulin, denoted by asterisks, are less abundant in precipitations with the Myc antibody since it was conjugated to agarose. B, HeLa cells (1 × 106) were transfected with 4 µg of pcDNA3.1/V5/His-TOPO-livin or pcDNA3.1-myc-survivin as above. Cell lysates prepared in RIPA buffer were immunoprecipitated and Western blotted with the indicated antibodies. C, in vitro processing of caspase-9 was tested by incubating [35S]methionine-labeled caspase-9 (2 µl) with in vitro translated Apaf-1 (6 µl), cytochrome c (10 µM), dATP (1 mM), and recombinant Livin (50 µM) at 30 °C for 1 h. The samples were resolved by SDS-PAGE and visualized with a PhosphorImager.

The effect of Livin on caspase-9 processing was tested in vitro. Incubation of procaspase-9 with Apaf-1, cytochrome c, and dATP can induce the processing of caspase-9, which can be inhibited by XIAP, c-IAP1, and c-IAP2 (14). Here, we found that addition of recombinant Livin directly inhibited caspase-9 processing as seen by a decrease in the 35-kDa fragment (Fig. 4C). Thus, Livin appears to act on caspase-9 in a similar manner to XIAP, c-IAP1, and c-IAP2 but distinct from Survivin.

The effect of Livin on DEVD-like caspase activity was tested in HeLa cells treated with TNF-alpha . TNF-alpha -induced apoptosis involves a complex signaling response that includes activation of caspase-8 at the receptor level leading to the processing of downstream caspases including caspase-3 and -7 (45). Caspase activity was measured using the fluorescent substrate DEVD-AFC, used to specifically detect DEVD-cleaving caspases (caspase-3, -6, -7, -8, and -10). Cell lysates were prepared from HeLa cells transfected with livin, the anti-apoptotic gene bcl-xL, or an empty vector which were subsequently treated with TNF-alpha and cycloheximide. Treatment with TNF-alpha and cycloheximide for 5 h led to ~7-fold increase in DEVD-AFC cleavage (Fig. 5A). However, cells transfected with livin exhibited reduced caspase activity by 15-20%, consistent with the transfection efficiency of these cells. Comparable levels of caspase inhibition were observed upon transfection with bcl-xL. These results demonstrate the ability of Livin to inhibit DEVD-like caspase activity in vivo, although Livin may not directly inhibit these caspases and it is possible that this suppression is simply the result of abrogation of caspase-9 processing upstream of caspase-3.



View larger version (31K):
[in this window]
[in a new window]
 
Fig. 5.   Livin inhibits TNF-alpha -triggered DEVD-like caspase activity and binds to active caspase-3 and-7 in vitro. HeLa cells (2 × 105) were transfected with 1 µg of pcDNA3.1/V5/His-TOPO-livin, pZeoSV2-Bcl-xL, or empty pcDNA3.1 control. Twenty hours post-transfection the cells were treated with TNF-alpha (1000 units/ml) and cycloheximide (30 µg/ml) for 5 h (hatched) or left untreated (solid). DEVD-AFC hydrolysis produced from cytosolic extracts was monitored over a 1-h period at 37 °C and quantified in relative fluorescence units (RFU). Error bars represent standard error of the mean, n = 3. B, equal amounts of recombinant activated caspase-3 or -7 (1 µg) were incubated with [35S]methionine-labeled Survivin, Livin, or the deletion mutants, Delta C86 (NH2 terminus) and 86-154 (BIR domain), which were prepared in vitro using the TNT T7 reticulocyte lysate system. Samples were immunoprecipitated with antibodies against the respective caspases and then resolved by SDS-PAGE and visualized by autoradiography. Aliquots of the in vitro translated (IVT) proteins (2 µl) were also analyzed in order to determine their relative abundance.

Next, we tested whether Livin and Survivin could bind to the active forms of caspase-3 and -7. Interactions between Survivin and caspases have been controversial. Initial studies showed that survivin prepared from whole cell lysates could bind to caspase-3 and -7 and also inhibit DEVD-like caspase activity (11), and there was one report that recombinant survivin could directly inhibit the activity of caspase-3 (12). While subsequent studies confirmed that Survivin was capable of binding to caspase-3 directly, in whole cell preparations Survivin bound preferentially to Cdk4 (13). Also, in a recent analysis of the x-ray crystal structure of Survivin, the authors found no direct interaction or inhibition of caspase-3 (46). In our experiments, [35S]methionine-labeled Livin and Survivin were prepared by in vitro transcription/translation and were incubated with recombinant active caspase-3 and -7 followed by caspase specific antibodies. Both caspase-3 and -7 interacted with Livin and Survivin, but not with the deletion mutant Delta C89 used as a negative control (Fig. 5B). The BIR domain of Livin was sufficient for caspase binding in agreement with its anti-apoptotic activity (Fig. 5B). A Biacore was used to determine the kinetics of the interaction between Livin and the active forms of caspase-3, and -7. Relatively potent affinity constants were observed for both of the caspases (24.6 pM for caspase-3 and 5.1 pM, for caspase-7).

While we found that Livin and Survivin could interact with caspases-3 and -7, we have yet to find any direct effect on inhibiting the activity of these caspase using the DEVD-AFC substrate (using up to a 1000-fold molar excess of IAP). Thus, there was an apparent discrepancy between the relatively strong binding between Livin and caspases-3 and -7 yet a lack of any effect on enzyme activity. In fact, other reports of IAP inhibition of caspase activity have been reported only when using a large (more than 5000) molar excess of IAP to caspase (10). Perhaps, in some cases either complexes with other unidentified proteins and/or post-translational modifications could enhance the inhibitory effects of Livin and Survivin on caspase activity.

Subcellular Localization of Livin-- Differential subcellular localization of the IAP family members have implied distinct roles in apoptosis regulation (18, 32). Staining for Livin was performed using antibodies against the V5 epitope tag in transfected HeLa cells. Livin was observed predominantly in the nucleus and in a filamentous pattern throughout the cytoplasm (Fig. 6). Furthermore, transfected Survivin, which was stained using antibodies against the Myc epitope, was observed in the same pattern as Livin (Fig. 6). Previous studies have shown that endogenous Survivin translocates to the nucleus during apoptosis and interacts with the cell cycle regulator Cdk4 (13). Survivin may also associate with microtubules of the mitotic spindle and regulate apoptosis during cell cycle progression (32). While the staining patterns observed here may be obscured due to the overexpression of the proteins, it does suggest that Livin and Survivin have similar subcellular localization. If the staining is an accurate reflection of endogenous Livin, it seems possible that Livin could play a role in preventing caspase cleavage of both cytoskeletal and nuclear proteins during apoptosis and perhaps is regulated by cell cycle proteins similar to Survivin.



View larger version (43K):
[in this window]
[in a new window]
 
Fig. 6.   Subcellular localization of Livin. HeLa cells (2 × 105) were transfected with 1 µg of pcDNA3.1-myc-survivin, pcDNA3.1/V5/His-TOPO-livin, or pcDNA3.1/myc-His-livin Delta N154. Twenty-four hours post-transfection, cells were fixed and then incubated with monoclonal antibodies against Myc or V5. Staining was detected using a fluorescein isothiocyante-conjugated goat anti-mouse antibody and visualized by epifluorescence, × 100 objective lens.

To determine the critical motifs required for the localization of Livin, HeLa cells were transfected with the deletion mutants Delta C86, 86-154, and Delta N154 each containing a Myc epitope tag used for staining. The truncated proteins Delta C86 and 86-154 produced aberrant diffuse staining (not shown). However, Delta N154, which contains the ~35 amino acid RING domain, was found in the same filamentous pattern as the wild-type protein (Fig. 6). These results suggest that the COOH-terminal region of Livin, and perhaps more specifically the RING domain, provides a sufficient signal for its proper subcellular distribution. While the function of RING domains have been largely enigmatic, they are often associated with mediating multiprotein complexes and in some cases co-precipitate with cytoskeletal proteins (47). Taking the functional and localization studies of Livin together, one can propose a modular model whereby the BIR domain mediates its anti-apoptotic activity and interaction with caspases, while the RING domain provides proper cellular localization. Interestingly, other IAP family members that have RING domains do not localize in the filamentous pattern seen here (18). This disparity suggests that the function of the RING domain, like the BIR domain, is not absolutely conserved but rather may depend on either the particular IAP and/or cell type in which it is expressed.

Antisense to Livin Induces Apoptosis-- Since depletion of Survivin using antisense was shown to produce defects in cell division as well as increased caspase activation and apoptosis (24, 30-33), we were interested in testing whether similar effects could be seen for Livin. An antisense construct was designed to include the entire coding region of livin cloned in the antisense orientation. There was no open reading frame in the antisense orientation of livin and therefore the construct did not result in the expression of new proteins. To verify that the antisense construct could reduce Livin expression, we compared the levels of overexpressed Livin protein in cells transfected with antisense to that of a control vector. To prevent apoptosis the cells were maintained in the presence of the general caspase inhibitor ZVAD-fmk. In both HeLa (Fig. 7A) and G361 (not shown) cells, transfection with the antisense construct abrogated the expression of Livin seen with the V5 antibody. In contrast, the antisense did not reduce the levels of Survivin (Fig. 7A), suggesting that the construct has a specific effect on Livin, and not on related IAP family members.



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 7.   Induction of apoptosis by livin antisense. A, HeLa cells (2 × 105) were co-transfected with 1.5 µg of pcDNA3.1/V5/His-TOPO-livin antisense, or control pcDNA3.1 vector, with 0.5 µg of pcDNA3.1/V5/His-TOPO-livin, pcDNA3.1-myc-survivin, or control. Cells were maintained in 100 µM ZVAD-fmk to prevent apoptosis. Cell lysates were prepared 24 h post-transfection and probed with monoclonal antibodies against the V5 epitope (Livin), Survivin, and glyceraldehyde-3-phos- phate dehydrogenase (GAPDH) (control) and visualized by ECL. B, HeLa, G361, and SW480 cells were co-transfected with 0.5 µg of the pTracer-SV-40 marker plasmid along with 1.5 µg of pcDNA3.1/V5/His-TOPO-livin (sense or antisense). GFP levels were measured by laser scanning cytometry 48 h post-transfection. At least 5000 cells were analyzed for each transfection. The graph indicates relative viability which was calculated based on the percent of GFP-positive cells as compared with the control, empty pTracer-SV-40 with pcDNA3.1. Error bars represent standard error of the mean, n = 3. C, G361 cells were transfected with 1.5 µg of pcDNA3.1/V5/His-TOPO-livin antisense, or control pcDNA3.1 vector. Cells were harvested 24 h post-transfection and DNA strand breaks were measured in situ using the TUNEL procedure with fluorescein isothiocyante-labeled dUTP. The percent of TUNEL-positive cells were assessed by laser scanning cytometry. At least 2000 cells were counted for each sample. Error bars indicate standard error of the mean, n = 3. D, HeLa cells were transfected with 1.5 µg of pcDNA3.1/V5/His-TOPO-livin (sense or antisense), or control pcDNA3.1 vector. DEVD-AFC hydrolysis was measured in cytosolic extracts prepared 24 h post-transfection. AFC levels were monitored over a 1-h period at 37 °C and recorded in relative fluorescence units (RFU). Error bars indicate standard error of the mean, n = 3.

The effect of the antisense construct on cell viability was analyzed by co-transfection with an empty pTracer vector producing the GFP marker. Transfections were performed in HeLa and G361 cells, which normally express livin, as well as SW480 cells, which do not have detectable levels of livin mRNA (Fig. 2). In HeLa or G361 cells the antisense decreased the percent of GFP-positive cells by 80-90% relative to the vector and sense controls (Fig. 7B). In contrast, transfection of the antisense into SW480 had little effect on GFP levels (Fig. 7B). These results demonstrate an effect of livin antisense on viability which correlated with livin expression.

To extend these results, apoptosis was evaluated in more detail by measuring DNA fragmentation and caspase activation. DNA fragmentation was assessed using the TUNEL assay. Transfection of the antisense construct into G361 cells triggered an ~8% increase in TUNEL staining (Fig. 7C). Typically, the transfection efficiency in these cells was 15-20% suggesting that about half of the transfected cells were TUNEL-positive. To test whether this correlated with an increase in caspase activity, cytosolic extracts of the transfected cells were incubated with the fluorescent substrate, DEVD-AFC. Transfections with the antisense triggered nearly a 3-fold increase in DEVD-AFC cleavage (Fig. 7D). Presumably, this increase in caspase activity is a consequence of diminished livin-caspase interaction.

These studies, along with those of Survivin, demonstrate significant roles for these IAP family members in maintaining viability. While the antisense to livin may act only on certain cell lines, it is interesting that at least in HeLa cells, apoptosis resulted from antisense to either livin or survivin. On the other hand, antisense against xiap had no effect on the viability of HeLa cells (data not shown). Furthermore, expression of survivin could not rescue from apoptosis triggered by livin antisense and vice versa. This suggests that Livin and Survivin are not redundant, with distinct and important roles in regulating apoptosis.


    ACKNOWLEDGEMENTS

We thank Dr. S. Hubbs for assistance with Biacore binding, L. Barnhart, M. Crickmore, and C. Schwarzman for generation of the caspase-9 and Apaf-1 constructs, and L. Hirata and P. Sherman for DNA sequencing.


    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: AstraZeneca Pharmaceuticals, Enabling Science and Technology, CRDL 145, 1800 Concord Pike, Wilmington, DE 19803. Tel.: 302-886-8043; Fax: 302-886-8830; E-mail: bruce.gomes@astrazeneca.com.

Published, JBC Papers in Press, October 9, 2000, DOI 10.1074/jbc.M003670200


    ABBREVIATIONS

The abbreviations used are: IAP, inhibitor of apoptosis protein; BIR, baculoviral IAP repeat; TNF-alpha , tumor necrosis factor-alpha ; PCR, polymerase chain reaction; MOPS, 4-morpholinepropanesulfonic acid; GFP, green fluorescent protein; AFC, 7-amino-4-trifluoromethylcoumarin; PAGE, polyacrylamide gel electrophoresis.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES


1. Deveraux, Q. L., and Reed, J. C. (1999) Genes Dev. 13, 239-252[Free Full Text]
2. LaCasse, E. C., Baird, S., Korneluk, R. G., and MacKenzie, A. E. (1998) Oncogene 17, 3247-3259[CrossRef][Medline] [Order article via Infotrieve]
3. Miller, L. K. (1999) Trends Cell Biol. 9, 323-328[CrossRef][Medline] [Order article via Infotrieve]
4. Ambrosini, G., Adida, C., and Altieri, D. (1997) Nat. Med. 3, 917-921[Medline] [Order article via Infotrieve]
5. Duckett, C. S., Nava, V. E., Gedrich, R. W., Clem, R. J., van Dongen, J. L., Gilfillan, M. C., Shiels, H., Hardwick, J. M., and Thompson, C. B. (1996) EMBO J. 15, 2685-2689[Abstract]
6. Liston, P., Roy, N., Tamai, K., Lefebvre, C., Baird, S., Cherton-Horvat, G., Farahani, R., McLean, M., Ikeda, J., MacKenzie, A., and Korneluk, R. G. (1996) Nature 379, 349-353[CrossRef][Medline] [Order article via Infotrieve]
7. Rothe, M., Pan, M.-G., Henzel, W. J., Ayres, T. M., and Goeddel, D. V. (1995) Cell 83, 1243-1252[Medline] [Order article via Infotrieve]
8. Thornberry, N. A., and Lazebnik, Y. (1998) Science 281, 1312-1316[Abstract/Free Full Text]
9. Deveraux, Q. L., Takahashi, R., Salvesen, G. S., and Reed, J. C. (1997) Nature 388, 300-304[CrossRef][Medline] [Order article via Infotrieve]
10. Roy, N., Deveraux, Q. L., Takahashi, R., Salvesen, G. S., and Reed, J. C. (1997) EMBO J. 16, 6914-6925[Abstract/Free Full Text]
11. Tamm, I., Wang, Y., Sausville, E., Scudiero, D. A., Vigna, N., Oltersdorf, T., and Reed, J. C. (1998) Cancer Res. 58, 5315-5320[Abstract]
12. Conway, E. M., Pollefeyt, S., Cornelissen, J., DeBaere, I., Steiner-Mosonyi, M., Ong, K., Baens, M., Collen, D., and Schuh, A. C. (2000) Blood 95, 1435-1442[Abstract/Free Full Text]
13. Suzuki, A., Ito, T., Kawano, H., Hayashida, M., Hayasaki, Y., Tsutomi, Y., Akahane, K., Nakano, T., Miura, M., and Shiraki, K. (2000) Oncogene 19, 1346-1353[CrossRef][Medline] [Order article via Infotrieve]
14. Deveraux, Q. L., Roy, N., Stennicke, H. R., van Arsdale, T., Zhou, Q., Srinivasula, S. M., Alnemri, E. S., Salvesen, G. S., and Reed, J. C. (1998) EMBO J. 17, 2215-2223[Abstract/Free Full Text]
15. Hinds, M. G., Norton, R. S., Vaux, D. L., and Day, C. L. (1999) Nat. Struct. Biol. 6, 648-651[CrossRef][Medline] [Order article via Infotrieve]
16. Takahashi, R., Deveraux, Q., Tamm, I., Welsh, K., Assa-Munt, N., Salvesen, G. S., and Reed, J. C. (1998) J. Biol. Chem. 273, 7787-7790[Abstract/Free Full Text]
17. Hay, B. A., Wassarman, D. A., and Rubin, G. M. (1995) Cell 83, 1253-1262[Medline] [Order article via Infotrieve]
18. Vucic, D., Kaiser, W. J., and Miller, L. K. (1998) Mol. Cell. Biol. 18, 3300-3309[Abstract/Free Full Text]
19. Chu, Z. L., McKinsey, T. A., Liu, L., Gentry, J. J., Malim, M. H., and Ballard, D. W. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10057-10062[Abstract/Free Full Text]
20. Yang, Y., Fang, S., Jensen, J. P., Weissman, A. M., and Ashwell, J. D. (2000) Science 288, 874-877[Abstract/Free Full Text]
21. Roy, N., Mahadevan, M. S., McLean, M., Shutler, G., Yarghi, Z., Farahani, R., Baird, S., Besner-Johnston, A., Lefebvre, C., Kang, X., Salih, M., Aubry, H., Tamai, K., Guan, X., Ioannou, P., Crawford, T. O., de Jong, P. J., Surh, L., Ikeda, J.-E., Korneluk, R. G., and MacKenzie, A. (1995) Cell 80, 167-178[Medline] [Order article via Infotrieve]
22. Xu, D. G., Crocker, S. J., Doucet, J.-P., St-Jean, M., Tamai, K., Hakim, A. M., Ikeda, J.-E., Liston, P., Thompson, C. S., Korneluk, R. G., MacKenzie, A., and Robertson, G. S. (1997) Nature Med. 3, 997-1004[Medline] [Order article via Infotrieve]
23. Tamm, I., Kornblau, S. M., Segall, H., Krajewski, S., Welsh, K., Kitada, S., Scudiero, D. A., Tudor, G., Qui, Y. H., Monks, A., Andreeff, M., and Reed, J. C. (2000) Clinical Cancer Res. 6, 1796-1803[Abstract/Free Full Text]
24. Grossman, D., McNiff, J. M., Li, F., and Altieri, D. C. (1999) Lab. Invest. 79, 1121-1126[Medline] [Order article via Infotrieve]
25. Kawasaki, H., Altieri, D. C., Lu, C.-D., Toyoda, M., Tenjo, T., and Tanigawa, N. (1998) Cancer Res. 58, 5071-5074[Abstract]
26. Lu, C. D., Altieri, D. C., and Tanigawa, N. (1998) Cancer Res. 58, 1808-1812[Abstract]
27. Saitoh, Y., Yaginuma, Y., and Ishikawa, M. (1999) Int. J. Oncol. 15, 137-141[Medline] [Order article via Infotrieve]
28. Papapetropoulos, A., Fulton, D., Mahboubi, K., Kalb, R. G., O'Connor, D. S., Li, F., Altieri, D. C., and Sessa, W. C. (2000) J. Biol. Chem. 275, 9102-9105[Abstract/Free Full Text]
29. Tran, J., Rak, J., Sheehan, C., Saibil, S. D., LaCasse, E., Korneluk, R. G., and Kerbel, R. S. (1999) Biochem. Biophys. Res. Commun. 264, 781-788[CrossRef][Medline] [Order article via Infotrieve]
30. Ambrosini, G., Adida, C., Sirugo, G., and Altieri, D. C. (1998) J. Biol. Chem. 273, 11177-11182[Abstract/Free Full Text]
31. Li, F., Ackermann, E. J., Bennett, C. F., Rothermel, A. L., Plescia, J., Tognin, S., Villa, A., Marchisio, P. C., and Altieri, D. C. (1999) Nat. Cell Biol. 1, 461-466[CrossRef][Medline] [Order article via Infotrieve]
32. Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., and Altieri, D. C. (1998) Nature 396, 580-584[CrossRef][Medline] [Order article via Infotrieve]
33. Olie, R. A., Simões-Wüst, P., Baumann, B., Leech, S. H., Fabbro, D., Stahel, R. A., and Zangemeister-Wittke, U. (2000) Cancer Res. 60, 2805-2809[Abstract/Free Full Text]
34. Kasof, G. M., Prosser, J. C., Liu, D., Lorenzi, M. V., and Gomes, B. C. (2000) FEBS Lett. 473, 285-291[CrossRef][Medline] [Order article via Infotrieve]
35. Barks, J. H., Thompson, F. H., Taetle, R., Yang, J.-M., Stone, J. F., Wymer, J. A., Khavari, R., Guan, X.-Y., Trent, J. M., Pinkel, D., and Nelson, M. A. (1997) Genes Chromosome Cancer 19, 278-285[CrossRef][Medline] [Order article via Infotrieve]
36. Hauser, H. P., Bardroff, M., Pyrowolakis, G., and Jentsch, S. (1998) J. Cell Biol. 141, 1415-1422[Abstract/Free Full Text]
37. Pan, G., Bauer, J. H., Haridas, V., Wang, S., Liu, D., Yu, G., Vincenz, C., Aggarwal, B. B., Ni, J., and Dixit, V. M. (1998) FEBS Lett. 451, 351-356[CrossRef]
38. Chinnaiyan, A. M., O'Rourke, K., Tewari, M., and Dixit, V. M. (1995) Cell 81, 505-512[Medline] [Order article via Infotrieve]
39. Stanger, B. Z., Leder, P., Lee, T.-H., Kim, E., and Seed, B. (1995) Cell 81, 513-523[Medline] [Order article via Infotrieve]
40. Sun, X., Lee, J., Navas, T., Baldwin, D. T., Stewart, T. A., and Dixit, V. M. (1999) J. Biol. Chem. 274, 16871-16875[Abstract/Free Full Text]
41. Yu, P. W., Huang, B. C. B., Shen, M., Quast, J., Chan, E., Xu, X., Nolan, G. P., Payan, D. G., and Luo, Y. (1999) Curr. Biol. 9, 539-542[CrossRef][Medline] [Order article via Infotrieve]
42. Oltvai, Z. N., Millman, C. L., and Korsmeyer, S. J. (1993) Cell 74, 609-619[Medline] [Order article via Infotrieve]
43. Sun, C., Cai, M., Gunasekera, A. H., Meadows, R. P., Wang, H., Chen, J., Zhang, H., Wu, W., Xu, N., Ng, S.-C., and Fesik, S. W. (1999) Nature 401, 818-822[CrossRef][Medline] [Order article via Infotrieve]
44. Deveraux, Q. L., Leo, E., Stennicke, H. R., Welsh, K., Salvesen, G. S., and Reed, J. C. (1999) EMBO J. 18, 5242-5251[Abstract/Free Full Text]
45. Green, D. R. (1998) Cell 94, 695-698[Medline] [Order article via Infotrieve]
46. Verdecia, M. A., Huang, H., Dutil, E., Kaiser, D. A., Hunter, T., and Noel, J. P. (2000) Nat Struct. Biol. 7, 602-607[CrossRef][Medline] [Order article via Infotrieve]
47. Saurin, A. J., Borden, K. L. B., Boddy, M. N., and Freemont, P. S. (1996) Trends Biochem. Sci. 21, 208-214[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.